Aptevo Therapeutics Inc.
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 38.94% | -62.24% | -56.25% | -9.98% | -112.09% |
| Gross Profit | -38.94% | 62.24% | 56.25% | 9.98% | 112.09% |
| SG&A Expenses | -10.42% | -21.09% | -12.33% | -9.95% | -7.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.03% | -20.55% | -26.34% | -9.97% | -16.92% |
| Operating Income | 0.03% | 20.55% | 26.34% | 9.97% | 16.92% |
| Income Before Tax | -1.87% | 19.47% | 25.98% | -474.06% | -20.01% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.87% | 19.47% | 25.98% | -474.06% | -20.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -43.76% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.93% | 19.47% | 25.98% | -346.45% | -27.17% |
| EBIT | 0.03% | 20.55% | 26.34% | 9.97% | 16.92% |
| EBITDA | -0.69% | 20.33% | 26.10% | 9.25% | 16.68% |
| EPS Basic | 98.24% | -- | -- | -- | -- |
| Normalized Basic EPS | 98.32% | -- | -- | -- | -- |
| EPS Diluted | 98.23% | -- | -- | -- | -- |
| Normalized Diluted EPS | 98.32% | -- | -- | -- | -- |
| Average Basic Shares Outstanding | 5,946.67% | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | 5,946.67% | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |